Hypertension (HT) is associated with cardiovascular events and increased mortality, and identification of persons at risk in due time is therefore important. Finding a biomarker to identify those at risk will enable early preventive treatment, and high-sensitivity cardiac troponin (hs-cTn) seems to be a highly relevant candidate. To gather the existing knowledge on the association between hs-cTn and future HT, a systematic literature review was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) reporting guidelines and using the PICOS system. Medline was searched until August 2018. Of 45 extracted papers, eleven papers were eligible for the study. None were randomized controlled trials. Three studies assessed hs-cTnI, eight studies assessed hs-cTnT. All studies found statistically significant associations between hs-cTn concentrations and future HT, but the studies included different types of blood pressure (diastolic, systolic, diurnal). Due to differences in troponin assay construction and test capability, a direct comparison of test performance in terms of specificity, sensitivity and predictive values was not possible, and a specific hs-cTn cutoff value for HT prediction could therefore not be defined. Furthermore, a number of conditions known to affect troponin concentrations (e.g. gender, renal function, and co-morbidities) were not sufficiently studied. All retrieved studies found significant associations between hs-cTn concentrations and future HT; although the findings are promising, the studies were too heterogeneous, and many conditions affecting troponin concentrations needs investigation at these low concentrations before hs-cTn can be considered a useful HT predictor.

高血压（HT）与心血管事件和死亡率增加相关，因此在适当的时候识别高危人群非常重要。寻找生物标志物以识别有风险的人将能够及早进行预防性治疗，高敏感性心肌肌钙蛋白（hs-cTn）似乎是高度相关的候选人。为了收集有关hs-cTn和未来HT关联的现有知识，在系统评价和荟萃分析的首选报告项目之后进行了系统的文献综述。（PRISMA）报告指南并使用PICOS系统。搜索Medline直到2018年8月。在45篇摘录论文中，有11篇论文符合研究条件。没有一项是随机对照试验。三项研究评估了hs-cTnI，八项研究评估了hs-cTnT。所有研究均发现hs-cTn浓度与未来HT之间存在统计学上的显着关联，但研究包括不同类型的血压（舒张压，收缩压，昼夜压）。由于肌钙蛋白测定结构和测试能力的差异，无法在特异性，灵敏度和预测值方面进行测试性能的直接比较，因此无法定义用于HT预测的特定hs-cTn临界值。此外，许多已知会影响肌钙蛋白浓度的疾病（例如性别，肾功能，和合并症）没有得到足够的研究。所有检索到的研究均发现hs-cTn浓度与未来HT之间存在显着关联。尽管研究结果令人鼓舞，但研究太不统一了，许多影响肌钙蛋白浓度的条件需要在这些低浓度下进行研究，然后才能将hs-cTn视为有用的HT预测因子。